Latest Breaking News On - செயல்திறன் நிலை - Page 24 : comparemela.com

Share this article Share this article ROCKLAND, Mass., Feb. 3, 2021 /PRNewswire/  EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that the US Food and Drug Administration (FDA) has approved TEPMETKO ® (tepotinib) following Priority Review for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET) exon 14 skipping alterations. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. The approval is based on results from the pivotal Phase II VISION study evaluating TEPMETKO as monotherapy in patients with advanced NSCLC with

United statesAndrea ferrisJulissa vianaPaulk paikDrug administrationGroup websiteEastern cooperative oncology groupOncology navigation centerThoracic oncology serviceSerono incMerck kgaGlobal head of development for the healthcareMerck kgaaAmerican cancer societyMemorial sloan kettering cancer centerPriority review